Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Modeling Time-Dependent Behavior of Concrete Affected by Alkali Silica Reaction in Variable Environmental Conditions.

Alnaggar M, Di Luzio G, Cusatis G.

Materials (Basel). 2017 Apr 28;10(5). pii: E471. doi: 10.3390/ma10050471.

2.

Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.

Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn RA, Hidalgo M.

Neoplasia. 2012 Aug;14(8):690-701.

3.

Acute administration of bronchodilators on exercise tolerance in treated COPD patients.

Vagaggini B, Nieri D, Malagrinò L, Antonelli S, De Cusatis G, De Simone C, Costa F, Paggiaro PL.

Pulm Pharmacol Ther. 2011 Feb;24(1):49-54. doi: 10.1016/j.pupt.2010.10.008. Epub 2010 Oct 21.

PMID:
20970517
4.

Clinical predictors of the efficacy of a pulmonary rehabilitation programme in patients with COPD.

Vagaggini B, Costa F, Antonelli S, De Simone C, De Cusatis G, Martino F, Santerini S, Paggiaro P.

Respir Med. 2009 Aug;103(8):1224-30. doi: 10.1016/j.rmed.2009.01.023. Epub 2009 Mar 21.

5.

Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.

Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Ramana Reddy MV, Rudek MA, Kulesza P, Donehower RC, Reddy EP, Hidalgo M.

Oncogene. 2009 Jan 29;28(4):610-8. doi: 10.1038/onc.2008.424. Epub 2008 Nov 24.

6.

Pharmacogenomic importance of ABCG2.

Cusatis G, Sparreboom A.

Pharmacogenomics. 2008 Aug;9(8):1005-9. doi: 10.2217/14622416.9.8.1005. Review.

7.

Pharmacogenetic pathway analysis of docetaxel elimination.

Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A.

Clin Pharmacol Ther. 2009 Feb;85(2):155-63. doi: 10.1038/clpt.2008.95. Epub 2008 May 28.

8.

Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib.

Gregorc V, Hidalgo M, Spreafico A, Cusatis G, Ludovini V, Ingersoll RG, Marsh S, Steinberg SM, Viganò MG, Ghio D, Villa E, Sparreboom A, Baker SD.

Clin Pharmacol Ther. 2008 Mar;83(3):477-84. Epub 2007 Aug 22.

PMID:
17713473
9.

Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer.

Jimeno A, Hallur G, Chan A, Zhang X, Cusatis G, Chan F, Shah P, Chen R, Hamel E, Garrett-Mayer E, Khan S, Hidalgo M.

Mol Cancer Ther. 2007 May;6(5):1509-16. Epub 2007 May 4.

10.

Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.

Li J, Cusatis G, Brahmer J, Sparreboom A, Robey RW, Bates SE, Hidalgo M, Baker SD.

Cancer Biol Ther. 2007 Mar;6(3):432-8. Epub 2007 Mar 29.

PMID:
17312388
11.

Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.

Cusatis G, Gregorc V, Li J, Spreafico A, Ingersoll RG, Verweij J, Ludovini V, Villa E, Hidalgo M, Sparreboom A, Baker SD.

J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.

PMID:
17148776
12.

An in vivo platform for translational drug development in pancreatic cancer.

Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, Tanaka K, Singh S, Salimi-Moosavi H, Bouraoud N, Amador ML, Altiok S, Kulesza P, Yeo C, Messersmith W, Eshleman J, Hruban RH, Maitra A, Hidalgo M.

Clin Cancer Res. 2006 Aug 1;12(15):4652-61.

13.

Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors.

Jimeno A, Daw NC, Amador ML, Cusatis G, Kulesza P, Krailo M, Ingle AM, Blaney SM, Adamson P, Hidalgo M; Children's Oncology Group.

Pediatr Blood Cancer. 2007 Sep;49(3):352-7.

PMID:
16425266
14.

Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.

Lepper ER, Baker SD, Permenter M, Ries N, van Schaik RH, Schenk PW, Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE, Mathijssen RH, Verweij J, Figg WD, Sparreboom A.

Clin Cancer Res. 2005 Oct 15;11(20):7398-404.

15.

An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.

Amador ML, Oppenheimer D, Perea S, Maitra A, Cusatis G, Iacobuzio-Donahue C, Baker SD, Ashfaq R, Takimoto C, Forastiere A, Hidalgo M.

Cancer Res. 2004 Dec 15;64(24):9139-43. Erratum in: Cancer Res. 2007 Aug 15;67(16):7937. Cusati, George [corrected to Cusatis, George].

Supplemental Content

Loading ...
Support Center